Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.

Polascik, Thomas J; Given, Robert W; Metzger, Charles; Julian, Sydney R; Vestal, James C; Karlin, Gary S; Barkley, Craig S; Bilhartz, David L; McWhorter, Laura T; Lacerna, Leo V

Polascik, Thomas J; Given, Robert W; Metzger, Charles; Julian, Sydney R; Vestal, James C; Karlin, Gary S; Barkley, Craig S; Bilhartz, David L; McWhorter, Laura T; Lacerna, Leo V.

Affiliation

Polascik TJ; Department of Urology, Duke University, Durham, North Carolina 27704, USA. polas001@mc.duke.edu

Urology ; 66(5): 1054-9, 2005 Nov.

Article in En | MEDLINE | ID: mdl-16286123

Subject(s)

Bone Density Conservation Agents/therapeutic use; Bone Neoplasms/complications; Bone Neoplasms/secondary; Bone Resorption/etiology; Bone Resorption/prevention & control; Diphosphonates/therapeutic use; Imidazoles/therapeutic use; Prostatic Neoplasms/pathology; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Prospective Studies; Zoledronic Acid

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Bone Neoplasms / Bone Resorption / Diphosphonates / Bone Density Conservation Agents / Imidazoles Type of study: Clinical_trials / Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Aged / Aged80 / Humans / Male / Middle aged Language: En Journal: Urology Year: 2005 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links